Date of Presentation

5-5-2022 12:00 AM

College

School of Osteopathic Medicine

Poster Abstract

Heparin is an anticoagulant medication, used to inhibit the formation of thrombi that pose arteriolar and vein-occlusive risk. The choice between starting a heparin infusion with or without an initial bolus is case dependent based on whether a patient is already anticoagulated and if so, foregoing an initial bolus. In contrast, both anticoagulated and non-anticoagulated patients share the same goal when receiving Heparin for various thromboembolic syndromes, and that is to be within aPTT target range of 1.5-2.5 or 45 to 75 seconds. Falling below goal range leads to a 20-25% recurrence of VTE, and aPTT above goal range has been shown to increase the probability of major bleeding by roughly 7% for every 10 second increase in aPTT1,5. The bolus dose has been shown to achieve therapeutic range faster than without the bolus, however this is often accompanied by overshooting the therapeutic range and necessity of titrating down on the subsequent infusion.

Keywords

anticoagulants, heparin, thrombosis, blood coagulation, pharmacological action

Disciplines

Cardiovascular Diseases | Chemicals and Drugs | Medicine and Health Sciences | Pathological Conditions, Signs and Symptoms | Therapeutics

Document Type

Poster

COinS
 
May 5th, 12:00 AM

A Brief Literature Review on Heparin: To Bolus Or Not To Bolus, That Is The Question

Heparin is an anticoagulant medication, used to inhibit the formation of thrombi that pose arteriolar and vein-occlusive risk. The choice between starting a heparin infusion with or without an initial bolus is case dependent based on whether a patient is already anticoagulated and if so, foregoing an initial bolus. In contrast, both anticoagulated and non-anticoagulated patients share the same goal when receiving Heparin for various thromboembolic syndromes, and that is to be within aPTT target range of 1.5-2.5 or 45 to 75 seconds. Falling below goal range leads to a 20-25% recurrence of VTE, and aPTT above goal range has been shown to increase the probability of major bleeding by roughly 7% for every 10 second increase in aPTT1,5. The bolus dose has been shown to achieve therapeutic range faster than without the bolus, however this is often accompanied by overshooting the therapeutic range and necessity of titrating down on the subsequent infusion.

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.